
AstraZeneca's COPD drug tozorakimab shows strong trial results, Citi forecasts $7B peak sales.
AstraZeneca's phase III trial results for tozorakimab in treating chronic obstructive pulmonary disease (COPD) showed significant reduction in flare-ups, especially in former smokers. The drug met its primary endpoint with a 29% to 34% reduction in e...





